FDA OKs Hep C Indication for Promacta

WASHINGTON (MedPage Today) — The FDA has approved eltrombopag (Promacta) for the additional indication of treating low blood platelet counts in patients with chronic hepatitis C.

Post a Comment

Comments are closed.